Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Simultaneous assessment of hepatic transport and metabolism pathways with a single probe using individualized PBPK modeling of 14CO2 production rate data.

Franchetti Y, Nolin TD.

J Pharmacol Exp Ther. 2019 Aug 9. pii: jpet.119.257212. doi: 10.1124/jpet.119.257212. [Epub ahead of print]

2.

Trimethylamine N-Oxide and Cardiovascular Outcomes in Patients with End-stage Kidney Disease Receiving Maintenance Hemodialysis.

Stubbs JR, Stedman MR, Liu S, Long J, Franchetti Y, West RE 3rd, Prokopienko AJ, Mahnken JD, Chertow GM, Nolin TD.

Clin J Am Soc Nephrol. 2019 Jan 21. pii: CJN.06190518. doi: 10.2215/CJN.06190518. [Epub ahead of print]

PMID:
30665924
3.

Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade.

Jacene HA, Youn T, DiPiro PJ, Hu J, Cheng SC, Franchetti Y, Shah H, Bellon JR, Warren L, Schlosnagle E, Nakhlis F, Rosenbluth J, Yeh E, Overmoyer B; Dana-Farber Cancer Institute Inflammatory Breast Cancer Program.

Clin Breast Cancer. 2019 Apr;19(2):146-155. doi: 10.1016/j.clbc.2018.11.010. Epub 2018 Nov 26.

PMID:
30584057
4.

Minimally invasive esophagectomy: results of a prospective phase II multicenter trial-the eastern cooperative oncology group (E2202) study.

Luketich JD, Pennathur A, Franchetti Y, Catalano PJ, Swanson S, Sugarbaker DJ, De Hoyos A, Maddaus MA, Nguyen NT, Benson AB, Fernando HC.

Ann Surg. 2015 Apr;261(4):702-7. doi: 10.1097/SLA.0000000000000993.

5.

10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.

Krajewski KM, Franchetti Y, Nishino M, Fay AP, Ramaiya N, Van den Abbeele AD, Choueiri TK.

Oncologist. 2014 May;19(5):507-14. doi: 10.1634/theoncologist.2013-0391. Epub 2014 Apr 22.

7.

Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria.

Krajewski KM, Nishino M, Franchetti Y, Ramaiya NH, Van den Abbeele AD, Choueiri TK.

Cancer. 2014 Mar 1;120(5):711-21. doi: 10.1002/cncr.28493. Epub 2013 Nov 21.

8.

Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.

Filbin MG, Dabral SK, Pazyra-Murphy MF, Ramkissoon S, Kung AL, Pak E, Chung J, Theisen MA, Sun Y, Franchetti Y, Sun Y, Shulman DS, Redjal N, Tabak B, Beroukhim R, Wang Q, Zhao J, Dorsch M, Buonamici S, Ligon KL, Kelleher JF, Segal RA.

Nat Med. 2013 Nov;19(11):1518-23. doi: 10.1038/nm.3328. Epub 2013 Sep 29.

9.

An adaptive two-stage dose-response design method for establishing proof of concept.

Franchetti Y, Anderson SJ, Sampson AR.

J Biopharm Stat. 2013;23(5):1124-54. doi: 10.1080/10543406.2013.813519.

10.

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, Liu Y, Tupper T, Ouyang J, Li J, Gao P, Woo MS, Xu C, Yanagita M, Altabef A, Wang S, Lee C, Nakada Y, Peña CG, Sun Y, Franchetti Y, Yao C, Saur A, Cameron MD, Nishino M, Hayes DN, Wilkerson MD, Roberts PJ, Lee CB, Bardeesy N, Butaney M, Chirieac LR, Costa DB, Jackman D, Sharpless NE, Castrillon DH, Demetri GD, Jänne PA, Pandolfi PP, Cantley LC, Kung AL, Engelman JA, Wong KK.

Nature. 2012 Mar 18;483(7391):613-7. doi: 10.1038/nature10937.

Supplemental Content

Loading ...
Support Center